insulin glargine / lixisenatide

This medicine is authorised for use in the European Union.


Suliqua is a medicine that is used together with metformin (another diabetes medicine), with or without SGLT-2 inhibitors (other diabetes medicines), for the treatment of adults with type 2 diabetes. It is used with appropriate diet and exercise to improve control of blood glucose (sugar) when the diabetes is not satisfactorily controlled.

The active substances in Suliqua are insulin glargine and lixisenatide.

This EPAR was last updated on 18/07/2023

Authorisation details

Product details
Agency product number
Active substance
  • insulin glargine
  • lixisenatide
International non-proprietary name (INN) or common name
  • insulin glargine
  • lixisenatide
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Sanofi Winthrop Industrie
Date of issue of marketing authorisation valid throughout the European Union
Contact address

82 Avenue Raspail
94250 Gentilly

Product information

17/07/2023 Suliqua - EMEA/H/C/004243 - N/0035

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.

Assessment history

How useful was this page?

Add your rating
9 ratings
7 ratings
16 ratings
12 ratings
1 rating